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ABSTRACT: 
 
Serum thymidine kinase 1 (TK1) activity determination is used as marker for tumor 
monitoring in both human and veterinary medicine. TK1 is an intracellular enzyme 
involved in the salvage pathway of DNA precursor synthesis. TK1 expression is cell 
cycle dependent and the activity increases markedly at the end of G1 and reaches a 
peak value in S phase and then declines rapidly in G2 ∕M. The pronounced 
proliferation in tumor cells result in a higher TK1 activity within cell. So 
determination of TK1 activity in tumors provides information regarding prognosis and 
effectiveness of treatment. In human medicine, a labeled radioactive substrate is used 
for measuring TK1 activity. Some studies have shown that this method can be used 
also in veterinary medicine. However, it has limitation for general use in animal 
practice since it is expensive and involves handling of radioactive material. In human 
medicine, anti TK1 antibodies have been used  to determine the concentration of 
serum TK1 in patients with carcinomas. This type of measurements has been 
successful and would be valuable to translate into veterinary medicine. The purpose of 
this study is to make the use of  anti-dog TK1 antibodies for detection of serum TK1. 
Anti bodies have been produced by immunizing the rabbit with synthetic piece of a 
dog TK1 peptide. Suspected band of serum TK1 has been found in the serum from 
dogs with tumors but not in the serum from healthy dogs using these antibodies. This 
study showed that anti dog TK1 polyclonal antibodies produced by affinity 
chromatography   binds to  serum TK1 with adequate capacity. It has been also shown 
that these antibodies can bind with both human and dog cytosolic TK1. These results 
are the first step in the development of an ELISA, which may provide clinical 
information about prognosis, risk of recurrence and effectiveness of antitumor therapy 
in veterinary medicine. 
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Background to the Veterinary medical problem: 
 
Dogs are prone to various neoplastic diseases, like lymphomas, mammary tumors and 
leukemia’s. When lymphocytes undergo transformation into cancerous cells, invasion 
of these cells into bone marrow and other organs (like spleen, thymus) of lymphatic 
system and forms solid tumors within these organs are called lymphomas (lympho 
sarcomas). They may originate from T-cells or B-cells. Lymphomas are the most 
common form of cancer in dogs; the annual incidence has been estimated as 13 to 40 
cases per 100,000 dogs. Lymphoma accounts for 7-24 % of all canine neoplasia. Dog 
breeds with high incidence of lymphomas includes Boxers, Bull Mastiffs, Basset 
Hounds and Scottish terrier; breeds with a low risk include Dachshunds and 
Pomeranians. Lymphomas are more commonly seen in 6-9 years old dogs and the 
etiology of the lymphomas is unknown and most likely multi factorial (Lane et al, 
2007). 
The Canine lymphoma staging system can be summarized as follows: lymphomas are 
staged with WHO scheme according to nodal involvement and divided into stages I, II, 
III, and IV and they are further sub-classified into a) asymptomatic  b) sick; followed 
by indicating the organ involvement (hepatic, splenic and bone marrow). Dogs that 
are sick with involvement of organs should be considered as clinically advanced stage. 
 
Table 1. Clinical stages of canine lymphoma 
 _________________________________________________________________ 
I. Involvement limited to a single node or lymphoid tissue in a single organ. 
II. Regional involvement of many lymph nodes with or without involvement 
of tonsils. 
III. Generalized lymph node involvement,  
IV. Liver and\ or spleen involvement (with or without stage III). 
V. Manifestation in the blood and involvement of bone marrow and\or other 
organ system(s). 
_________________________________________________________________ 
Each stage is sub classified into A (with systemic signs) and B (without systemic 
signs). 
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Clinical observations: 
The clinical observations mainly depend on the extent and location of tumor. Multi 
centric lymphoma is the most common form with generalized lymphadenopathy, 
hepatosplenomegaly and most of the dogs are asymptomatic but nonspecific signs like 
anorexia, vomiting, diarrhea, asicites and fever are common. In alimentary lymphoma 
gastro-intestinal signs such as vomiting, diarrhea, weight loss, and malabsorption are 
common. Mesenteric lymph nodes, spleen and liver may be involved. The mediastinal 
form of lymphomas is characterized by enlargement of the craniomediastinal 
structures or thymus. Respiratory distress, exercise intolerance, polyuria from 
hypocalcaemia are frequently observed. Cutaneous lymphoma is usually generalized 
and skin becomes more erythemtous, thickened, ulcerative and exudative. Sometimes 
oral involvement also occurs (Lane et al, 2007).  
  Diagnosis:  
Physical examination of lymph nodes, complete blood picture, biopsy and 
microscopic examination are required for an accurate diagnosis in the early stages of 
lymphomas. Fine needle aspiration and radiographic examination are useful in 
different stages of lymphomas. Malignant lymphomas cannot be cured completely, 
however, early detection and efficient chemotherapy can control the disease for long 
time. 
Prognosis:  
The prognosis of canine lymphoma depends on various factors like location of tumor, 
extent of the disease, presence and absence of clinical signs. Immunophenotyping of 
the lymphomas into B- cell and T- cell type may assist in the prognosis. Another 
prognostic indicator involves the use of cell proliferation markers in tissue specimens. 
Several attempts have been made to use these markers for prognosis and relapse of the 
lymphomas in dogs. Serum alpha 1 acid glycoprotein concentration was used for 
predicting the relapse of malignant lymphoma. Alpha-fetoprotein can be a good 
marker in advanced stages of malignant lymphomas, where the concentration of this 
protein is high (von Euler et al, 2004). 
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Biomarkers in Veterinary Medicine: 
Cell proliferation markers commonly used in veterinary medicine are Ki-67, 
argyrophilic nuclear organizing regions (AgNOR), Mitotic index, proliferation cell 
nuclear antigen (PCNA), lactate  dehydrogenase (LDH) (Kiupel et al, 1999). 
Monoclonal antibody, Ki-67 recognizes a nuclear antigen present in proliferating cells 
and permits an immunohistochemical method of assessing tumor cell proliferative 
fraction. It is expressed in all phases of active cell cycle (G1, S, G2 and M) and it is 
absent in resting cells (G0) (Leong et al, 1995). AgNOR is a good marker for the 
prognosis of lymphoma. The quantity of the AgNOR not only reflects the percentage 
of cells in  cycle but it also increases when the cell cycle is faster and AgNOR counts 
correlates well with the tumor grade (Kiupel et al, 1998). Studies on AgNOR 
demonstrated significant predictive potential for remission in treated and untreated 
cases of canine lymphoma (kiupel et al, 1999). However, histopathological 
examination of AgNOR does not help for disease monitoring. AgNOR is associated 
with problems in interpretation and is dependent on type of  the fixation method, 
temperature and staining time. Mitotic index is an indirect measure based on 
quantification of the proportion of mitotic cells in a histopathologic specimen and it is 
easier to perform than AgNOR and Ki-67 assessment (Romansik et al, 2007). PCNA 
is produced in late G1 phase and throughout S-phase, but it can be detected in all 
proliferating cells because of long half life, High concentrations of PCNA are detected 
in S phase. It has been used to predict prognosis in melanomas in dogs and cats (Roels 
et al, 1999). In one study, plasma lactate dehydrogenase (LDH) was used for 
evaluation of disease progression in malignant lymphoma of dogs (Nakamura et al, 
1997).  They found elevated levels of plasma LDH in tumors and in some hemolytic 
diseases. In certain serum samples of dogs with tumors, they did not find any increase 
in the plasma LDH level.  Furthermore, the sensitivity and specificity of LDH is very 
low (Nakamura et al, 1997). Thymidine kinase 1 expression both at the RNA and 
protein level has been used extensively as a marker for proliferating cells and TK1 is 
one of the protein, whose abundance is most closely correlated to the S-phase.  
Because of its association with S phase, it is a good proliferative marker for 
monitoring and prognosis of tumor diseases. 
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Introduction to the project: 
Thymidine kinase (TK) is a cytosolic enzyme involved in the pyrimidine salvage 
pathway, which are building blocks of DNA. Thymidine kinase catalyzes the 
conversion of deoxythymidine to deoxythymidine monophosphate (dTMP) in the 
presence of ATP by transferring the γ- phosphate group. This phosphorylation step is 
often a rate-limiting step and deoxythymidine monophosphate is subsequently 
phosphorlyated to di and triphosphates before serving as a substrate for DNA 
synthesis. TK enzymes in mammalian cells appear in two forms, a cytosolic 
thymidine kinase (TK1) and the mitochondrial (TK2) form. Thymidine kinase 1 (TK1) 
is present in the cell cytoplasm and is involved in cell proliferation. TK2 is involved 
in mitochondrial DNA synthesis, which is independent of the cell cycle (von Euler et 
al, 2006). 
TK1 plays a primary role in regulation of  intracellular thymidine nucleotide pools 
during the cell cycle. The level of TK1 increases from late G1 to late S phase and 
early G2 phase in both proliferating and tumor cells. Thymidine kinase may also 
appear in the body fluids because of cells with disrupted spindle apparatus (von Euler 
et al, 2004). TK1 or TK1 like genes seems to be widely distributed in many organisms 
from plants to humans, including bacteria and viruses (Welin et al, 2004). The human 
TK1 gene is 12.9 kb with seven exons. The 1241bp cDNA with  an open reading 
frame of 702 bp,  encoding a 234 amino acids long protein with a molecular weight of 
25.5 kDa and TK1 gene is located on chromosome 17 (Eriksson et al, 2002). To 
characterize serum TK1 reducing agent treatment were used and only high 
concentration of DTE (Dithioerythritol, 400 mM) showed effects on the molecular 
forms of TK1 going from more than 700 kDa to about 100 kDa (Karlström et al, 
1990). In human medicine TK1 activity is measured by using a commercially 
available assay; the Prolofigen TK-REA (radio enzymatic assay), where a radioactive 
substrate analogue is added. It then measures the amount of converted substrate per 
unit time, which represents the TK activity in serum. 
In one study, they used the same method to determine the TK1 activity in the serum of 
dogs with malignant lymphoma and non-hematological or healthy ones (von Euler et 
al, 2004). Serum TK1 activity was significantly higher in lymphoma than in normal 
dogs. Average TK1 activity after complete remission was not significantly different 
compared with healthy dogs. Thus, measuring TK1 activity in dog’s serum serves as a 
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tumor marker providing information regarding prognosis and risk of relapse in dogs 
with tumors (von Euler et al, 2004). One publication has described the use of plasma 
thymidine kinase activity in diagnosis and monitoring of lymphomas and leukemia in 
dogs (Nakamura et al, 1997). 
In human medicine, serum TK1 activity has been used for estimating the extent of 
tumor disease and information of the prognosis of leukemia’s, multiple myelomas, 
Hodgkin’s lymphoma and non-Hodgkin’s lymphomas (Wu et al, 2003). Serum TK1 
activity has been determined by using commercially available TK-REA. This assay 
provides prognostic information of malignancies and some cases it can aid in the 
choice of therapy (Topolcan et al, 2008). A non-radiometric TK enzyme linked 
immunosorbent assay (ELISA) was developed by using 3'-azido-2'-deoxythymidine 
(AZT) as substrate, which is phosphorylated selectively by TK1 in the serum. 
Furthermore, a competitive ELISA measures the amount of AZT monophosphate 
using goat polyclonal antibodies (Öhrvik et al, 2004). Recently, a Liaison assay was 
developed. It  is a non-radiometric assay and  technically more accurate, reliable in 
measuring the TK1 activity in dogs with lymphomas. In brief, TK1 in the tumor 
serum sample catalyzes phosporylation of 3'-azido-thymidine (AZT) to the 
corresponding 5'- monophosphate(AZTMP). In the second step, the produced 
AZTMP competes with AZTMP conjugated to isoluminol(AZTMP-ABEI) for 
specific antibodies bound to magnetic beads. Free AZTMP-ABEI is removed by 
washing and the amount of bound AZTMP-ABEI is determined by 
chemiluminescence (von Euler et al , 2008). 
The Biovica Company Uppsala (Sweden) has developed the very sensitive Divi Tum 
assay, which is a non-isotopic method and uses bromo-deoxyuridine as substrate for 
TK followed by its incorporation into an oligonucleotide attached to a solid support 
(refer www.biovica.com). Even though we have, many assays to determine the serum 
TK1 activity in dogs most of them needs special equipment that are expensive. The 
dog TK1 gene (amino acid) sequence shows 88.5% similarity with the human. TK1 
sequence diversity is 9.1% and most of the differences in sequence is seen in the C-
terminal part (Fig 1)  
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     Dog:      AYTKRLGSEK EVEVIGGADKYHSVCRLCYFKKASGPPMGLDSERNKENVL  210 
HUMAN:       AYTKRLGTEKEVEVIGGADKYHSVCRLCYFKKASGQPAGPDNKEN-----         210  
 
     DOG:         VLVPGKPGEGKEATGVRKLFAPQHVLQCSPAN    243  
HUMAN:       CPVPGKPGE------ AVAARKLFAPQQILQCSPAN      235  
                                                              
Fig 1:  The sequence of  Dog and Human TK1 (160-243) . Red color indicates the 
differences in the amino acid sequence. The underlined sequence amino acids (196-
223) are used for immunization of rabbit. 
 
The use of TK1 serum tests in humans has increased recently and most of these tests 
are based on activity measurement with radio labeled substrates. In veterinary practice, 
the commercially available tests are not a convenient alternative because of the need 
for a special instrument. Still the result with the Liaison TK assay serves as a good 
indicator for the value of this type of information for prognosis and monitoring of 
dogs with malignant lymphoma.  
In human medicine anti human TK1 anti bodies have been utilized for measuring the 
serum TK1 levels in various conditions, e.g. Lung cancer, colorectal and mammary 
cancers (He et al, 2000). However, it has not been described by any method that 
makes use of dog TK1 antibodies. So it would be interesting to produce the dog TK1 
antibodies and evaluate them further whether they can provide a simpler method for 
prognosis of tumors in dogs. Three different rabbits Ulrika (U), Dingo (D) and Kurtis 
(K) were immunized with synthetic peptide (amino acids 196-223) by Agri Sera AB 
(Umea Sweden). Anti sera were already collected from these rabbits after different 
periods of immunization before starting project. 
The main purpose of this project is to purify these antisera using affinity 
chromatography, which was produced by coupling the C-terminal peptide shown in 
Fig 1 to a Sepharose 4B matrix. These purified antibodies are used to study serum 
TK1 and eventually determine its concentration in various serum samples. Serum 
TK1 activity measurements were determined with radioactive thymidine as substrate. 
Another objective of this work was to collect blood samples from dogs with tumor 
diseases and analyze TK1 levels, trying to find a correlation with disease condition 
and serum TK1 levels.  
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Materials and methods:  
All serum samples were collected from dogs with tumors at the Department of clinical 
medicine, small animal clinic, SLU. Cell cultures from dog MDCK (madin Darby 
canine kidney cell lines) and the human T-lymphoblast cell lines like CEM TK
+
  and 
TK
−
 variants were also used. 
Purification of rabbit anti TK1 antibodies by Sepharose coupled with C-terminal 
TK1 peptide: 
CNBR-activated Sepharose 4B (1 gram in final volume of 3.5 ml) was treated with 
HCl  to remove the preservatives and mixed with  dog peptide i.e. (CPMGLDS 
RENKENVLVLVPGKPGEGKEANH2) at a concentration of 2 mg ∕ml in 3 ml of coupling 
buffer (0.1 M NaHCO3 pH-8.3 containing 0.5 M NaCl). The coupled Sepharose was 
washed with five medium volumes of coupling buffer and remaining active groups 
were blocked by transferring the medium to 0.1 M Tris-HCl buffer, pH 8.0. The 
Sepharose was then treated with three cycles of alternating 0.1 M acetate buffer, pH 
4.0 containing 0.5 M NaCl and 0.1 M Tris-HCl, pH 8.0. Finally, the column was 
washed with PBS. For purification of anti TK1 antibodies filtered 15 ml of rabbit anti-
serum was diluted in PBS to 50 ml and loaded on the affinity column. It was washed 
with 20 ml (50 mM Tris-Cl, pH 8.0; 0.1% Triton X-100; 0.5 M NaCl) followed by (50 
mM Tris-Cl, pH 9.0; 0.1% Triton X-100; 0.5 M NaCl), with 50 mM sodium 
phosphate, pH 6.3; 0.1% Triton X-100; 0.5 M NaCl. Elution of bound rabbit anti TK1 
antibodies was performed with 20 ml 50 mM Glycine –HCl, pH  2.5; 0.1% Triton X-
100; 0.15 M NaCl into  tubes containing 4 ml of 1 M Tris-Cl, pH 9.0, to neutralize the 
samples.  
Determining the protein concentration: 
The protein concentrations were determined using the Bio-rad protein assay. The 
reference used here was BSA (bovine serum albumin) in PBS. 
The Bio-rad reagent was diluted with water and four different concentrations of BSA 
(2.7, 5.4, 7.1 and 10.8 µg respectively) has made to set reference. Two samples of 
antibody solution were used. Absorbance was measured at 595 nm and a reference 
graph was created with the BSA standards. With the help of the graph, the 
concentration of antibody protein was determined. 
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 Dot blot immuno assays: 
The TK1 levels in serum samples were measured using the enhanced 
chemiluminscent (ECL) dot blot assay (He et al 2000). In this assay, 3 µl of serum is 
applied to the nitrocellulose membrane (Hybond TM-C, Amersham). Recombinant 
dog TK1 was used as standard. The membranes were left to dry and then blocked with 
10 % non-fat milk in TBS for one hour. The membranes were incubated with primary 
antibody (1.25 µg ∕ml) for two hours and washed with TBS-T (0.1% Tween 20) for 15 
minutes. Secondary antibodies conjugated with HRP were added (2 ng ∕ml) and 
agitated for one hour (He et al, 2000). Then the membranes were washed with TBS-T 
for 15 min and ECL substrate applied to membrane for 1 min, and then the membrane 
was exposed to X-ray film. The serum TK1 levels were determined by measuring the 
intensity of the spot and compared to a TK1 standard. 
 
Depletion of albumin and IgG from the serum: 
Proteoprep blue albumin and IgG depletion kit (SIGMA, USA) was used for depletion 
of albumin. This kit removes more than 85% albumin and 70% of IgG in the serum 
samples. It involves two steps  a) column equilibration: medium slurry of 0.4 ml was 
transferred to a spin column. Storage solution was removed by centrifugation. 
Equilibration buffer (0.4 ml) was added to the spin columns and centrifuged.  The 
buffer from collection tube was discarded after centrifugation and replaced with new 
collection tube. Then this column was used for serum depletion.  b) Depletion of 
albumin and IgG from the serum samples: Serum samples of 100 µl were added to 
spin column and allowed for 10 minutes at room temperature. So that albumin and 
IgG in serum are bound to the slurry in the spin column. Centrifugation and reloading 
of the elution to the same spin columns removed an additional 5% of the albumin. The 
depleted serum  in collecting tube  was used for further evaluation. 
 
Isolation of serum TK1 using the anti TK1 antibody Sepharose: 
Serum samples 100 µl from healthy dogs and dogs with tumors after depletion of 
albumin were diluted with 100 µl of TBS and incubated with the anti dog TK1 
antibody Sepharose (200 µl). The samples then agitated at 4°C for 3 hours followed 
by centrifugation. The sepharose was washed two times with TBS, one time with 
TBS-T and one time with TBS. Then 40 µl of sample buffer (containing 0.5 M Tris-
HCl, pH 6.8, glycerol, 10%  (w\v) SDS, and 0.1% bromophenol blue) was added to 
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the Sepharose and incubated at room temperature for 30 minutes to elute  bound 
serum proteins. These samples were heated at 95°C for 5 minutes and analyzed by 
SDS-PAGE. 
Western blot: 
SDS-PAGE and electrophoretic transfer was done as described in Amersham life 
sciences western blotting protocols. Samples were loaded on the gel and run for 1 
hour at 160 V and 6 µl of  marker (Fermentas, USA)  for reference protein molecular 
weights.  Proteins were transferred to PVDF membranes (GE HealthCare) at 90 V for 
50 min. Membrane was rinsed 3×5 min with TBS buffer (pH 7.6) and blocked in 
TBS-T (5% BSA) buffer. The membrane was incubated with primary antibody (1.25 
µg ∕ml) and then incubated with goat-Anti rabbit F (ab)2 fragment and avidin HRP 
conjugated (Jackson, USA). The membrane was briefly rinsed with TBST buffer 
twice, and then washed once for 15 min and twice for 5 min with TBST buffer. The 
membrane was incubated with the ECL reagents (GE HealthCare) for precisely 1 min 
at room temperature and then placed in film cassette for 2-5 min exposure (hyper 
film-ECL). 
Immunoprecipitation: 
Immnuoprecipitation with Protein-G sepharose was done as described by (GE 
HealthCare). Serum samples of 200 µl along with buffer (containing TBS, pH 7.6, 1 
mM befa block, 1% BSA and purified anti dog TK1 antibodies of  2µg ∕ 500µl) to 
make final volume of 500µl but in cell extract the protein concentration was 500µg.  
These tubes incubated at 4°C overnight.  Then the samples were mixed with 100µl of 
Protein-G sepharose. These tubes were kept at 4°C with slight agitation for 4 hours. 
The Sepharose beads were centrifuged and washed with TBS two times, one time 
with TBS-T and then with TBS. Protein-G sepharose was incubated with sample 
buffer (0.5M Tris-HCl, pH 6.8, glycerol, 10% (w\v) SDS, 0.1% bromophenol blue at 
room temperature for 20 minutes to elute the antibody complexes. The samples were 
analyzed by western blotting as described. 
Determination of enzyme activity: 
Enzyme activity of the serum samples was determined by using radio labeled ³H-
thymidine as a substrate. The reaction was started by adding 20 µl TK assay buffer 
(0.1 M Tris-HCl, 0.15 M NaCl, 5 mM MgCl2, 5 mM NaF, 2 mM DTT, and 5 mM 
ATP) to 20 µl of serum samples. The substrate was phosporylated by enzyme in 
serum with ATP as phosphate donor. The reaction was interrupted at different time 
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points (30, 60, 120 and 240 min) to measure the amount of product formed. A small 
fraction (10 µl) of reaction mixture was transferred to DE-81 paper disks. These disks   
were washed two times with 1mM ammonium formate for 10 minutes of each. Then 
paper disks were incubated in 1 ml of (0.1 M HCl and 0.2M KCl) for 45 minutes to 
elute the product which were measured by scintillation counting. The results are 
expressed in pmol  ∕ min.  
 
FPLC (fast protein liquid chromatography):  
FPLC was used for rapid separation of proteins from complex mixtures. Sera and cell 
extracts (100 µl) were diluted two fold with buffer (0.01 M Hepes pH -7.6, containing 
0.15 M NH4Cl and NaN3) and then filtered. 200 µl samples were fractioned by 
sepharose 12 chromatography (GE HealthCare) in a column of 1.0×30 cm. Protein 
content was monitored continuously at 280 nm. The column was eluted with the same 
buffer and  350 µl of 24 fractions were collected. 200 µl of these fractions are 
precipitated with 10% TCA and did western blot as described above.  Four  proteins; 
alpha 2 –macro-globulin, BSA, Ova albumin and Horse myoglobulin with the 
molecular weights of 700, 66 ,45 and 17 kDa were used as molecular weight markers.  
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Results: 
Sera were collected from rabbits 4 weeks after immunization. Anti serum was loaded 
on affinity column made with  the C terminal region of dog  TK1. The bound anti 
TK1 antibodies from rabbit (D) and rabbit (U) were purified in this way. The 
concentration of antibodies was determined by the Bio-rad assay. Protein 
concentration in case of the rabbit (D) antibodies was 0.8 mg ∕ ml and from rabbit (U) 
0.5 mg ∕ ml. The purified antibodies from D (Fig 2) were tested with human 
recombinant TK1 (234 aa + his tag) and dog recombinant TK1 ∆12 (230 aa + his tag) 
(see appendix)  
  
               1         2       3       4       5      6                     
           
 
 
Fig 2: Western blot analysis with purified rabbit (D) antibody (1.25 µg ∕ml) with 
human and dog recombinant TK1. Lane 1-3 are dog recombinant TK1∆12 (2, 1 and 
0.5 ng); 4-6 are human recombinant TK1 (2, 1 and 0.5 ng). 
 
Normally  TK1  exits as dimer  and by activation  with ATP ( adenosine triphospate) 
it  converts  into tetramer. The sub unit of TK1 in lower region at 28 kDa in case of 
both human and dog (Fig 2) ( see appendix page 29 and 30).  In Fig 2, an apparent 
dimeric form of TK1 is seen as strong band between the 52 kDa and 72 kDa.  To 
analyze the upper band of TK1, mass spectrometry of the bands in that region was 
performed. The band was conformed as TK1 , which corresponds to molecular weight 
of 66 kDa (approx). peptide analysis results were shown in appendix ( page 32).                                            
 
                                   
 52 kDa 
 28 kDa 
 72 kDa 
 16 
  
The anti dog TK1 antibodies from D reacts with cytosolic TK1 in crude cell extracts 
from dog MDCK cells but also with human TK1 in CEM TK
+
 cells but no band was 
seen in CEM TK
−
 cell extracts (Fig 3). 
                                                                                 
      1           2           3           4             5                               3            4          5 
 
 
Fig 3:  Western blot analysis with TK1 antibody from D (1.25 µg ∕ml) the absence (A) 
and in presence (B) of an excess of the antigen peptide (0.1 µg ∕ml). Lane 1, 2 are Dog 
recombinant TK1 (0.25, 0.05 ng) 3, 4, 5 are extracts from cell lines (CEM TK
+
, 
MDCK, CEM TK
−   
approx 
 
100 µg protein in each case).  
   
The band at 26 kDa, which was found in both CEM TK
+
 and MDCK cell extracts 
corresponds to cytosolic TK1 and  the band was absent in CEM TK
−
  cell extract.  
MDCK extract from a cell culture grown to high density cell lines were tested and in 
this case a double band was found in the region corresponding to cytosolic TK1. 
There were no bands on membrane B in lower TK1 band region demonstrating that an 
excess of peptide could block the reactivity with all the polypeptides seen in fig 3A. 
The band that appeared at 52 kDa is most likely not related to TK1 since this band 
was observed  in extracts from TK
− 
cells and also on the membrane B. 
 
 
 
 
 
 
 
 26 kDa 
 52 kDa 
A B 
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Anti dog TK1 antibodies from U and D were used to test the reactivity with human 
and dog recombinant TK1 and cell extracts.  
 
       1            2            3              4          5              1         2            3             4            5 
 
 
 
Fig 4:  Western blot analysis with anti dog TK1 antibodies from U (A) and D (B). 
Lane 1  is recombinant dog TK1 (0.5 ng) 2, 3 are human TK1 (2 and 1 ng) 4 is 
MDCK cell extracts from high density cultures, 5 is MDCK cell extract from 
exponentially growing cells and a  total  of 25 µg protein was tested. 
  
The membrane with antibodies from rabbit U has shown light band with dog 
recombinant TK1 (indicated by arrow) and no reactivity with cytosolic TK1 from dog 
cell extracts (Fig 4A). Anti bodies from rabbit D showed good reactivity with both 
dog and human recombinant TK1 (Fig 4B).  the sub unit of  cytosolic TK1 (26 kDa) 
was appeared as single  in MDCK extract from exponentially growing cells. This was 
different as double band was appeared in this region in MDCK cell extract from high 
dense culture( Fig 3A). 
Based on results from Fig 4B anti bodies from rabbit D were used for evaluation of 
TK1 from serum samples (serum from healthy dog and dogs with tumor disease). D 
anti bodies were coupled to Sepharose 4 B. Albumin was depleted from the serum 
samples before incubating with D anti TK1 anti body sepharose.    
 
 
 
 
26 
26 kDa 
 52 kDa 
                                                                                 
B 
A 
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       1         2            3           4           5                              2          3             4            5 
 
 
Fig 5: Western blot analysis of serum samples purified with D antibody Sepharose. 
Lane  1 is recombinant dog TK1 (0.5 ng), 2 is serum from a healthy dog and 3, 4, 5 
are serum from dogs with tumor diseases. There were several bands observed on the 
membrane where no primary antibody was added, most likely because of cross 
reactivity to some serum proteins by the secondary anti rabbit antibodies. 
 
In Fig 5A there was clear band just below recombinant TK1 (indicated by arrow) at a 
molecular weight of 28 kDa in sera from dogs with tumor diseased but not in sera 
from healthy dogs.  This band was not seen in Fig 5B, and could therefore represent a 
form of serum TK1. The recombinant TK1 contains his tag protein (1.5 kDa) which 
may explain why it has a higher molecular weight than the presumed serum TK1 
(appendix page 32).  
Effects of different reducing agents on serum TK1:  Reducing agents like DTT 
(dithiothreitol) or DTE at different concentrations were used because in earlier study 
(Karlström et al, 1990) it was observed that the molecular weight of TK1 was affected 
by these reducing agents in FPLC gel filtration analysis. Here we performed similar 
analysis but  serum samples treated with reducing agents and performed western blot 
(up to 100 mM).  This had no clear-cut influence on the apparent gel filtration pattern 
of TK1 with regard to high molecular and low molecular weight forms and that was 
different from what was found previously. However, in this case we did not use the 
very high DTE concentration (400 mM) which was done in the study by Karlström et 
al.  
 
     52 kDa 
 28 kDa 
   A   B 
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         1          2             3           4                     1             2                  3           4 
    
 
Fig 6: Western blot analysis of serum samples treated with reducing agents. In the 
figure 6, 1 and 2 are sera treated with 200 mM of DTT and 3, 4 with 200 mM of DTE. 
1, 3 are sera from dog with tumor disease and 2, 4 are sera from healthy dogs. 
 
In A the membrane is incubated with purified D antibodies and  B is without of 
primary antibody. Suspected TK1 band appeared below the molecular weight of 28 
kDa in sera from dogs with tumor disease (indicated by arrow) but not in sera from 
healthy dogs (see  Fig 5A). The strong bands  in the upper region are mainly due to 
cross reactivity of secondary antibodies with some serum proteins. Furthermore these 
bands were seen on the membrane without primary antibodies (Fig 6B). Reducing 
agents treatment was helpful in reduction of many unspecific proteins that appeared 
on membrane with  direct serum samples. 
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      52 kDa 
     A                                                                   B                                                                         
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Fig 7.  Western blot analysis of  different FPLC fractions ( fr) .In the  Fig 7 , different 
FPLC fractions ( 14,16, 18 and 20) of  both healthy and  tumor diseased  dog serum 
samples treated with 10% TCA ( trichloroacetic acid) and recombinant dog TK1 of 
0.5 ng.  Membrane A  is with FPLC fractions of healthy dog serum incubated with 
antibodies from D. Membrane is with tumor diseased dog serum sample FPLC 
fractions incubated with antibodies from D. 
In  FPLC fractions of healthy dog serum samples (Fig 7A)  no bands were observed 
around the molecular weight of 28 kDa  but in the case of tumor diseased serum 
fractions suspected band of  TK1 sub unit was detected. In the ( Fig 7B) both dimer 
(14 and 16 fractions) and monomer ( fraction 20) forms of serum TK1 were identified.    
 
 
 
 
 
 
 
 
 
 
 
 
 
        52 kDa 
 28  kDa 
      72 kDa 
A                                                                              B                                                 
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Discussion:    
The peptide sequence  used to immunize rabbits was from amino acids 196-223, 
which is the C-terminal part and most variable region in human and dog TK1  
sequence. The possible explanation for differences in reactivity of these two anti TK1 
antibodies could be its epitopes. The epitope of  D antibodies  may present in both the 
human and dog amino acid sequence, since it was able to recognize both human and 
dog TK1. However, the epitope for the U antibodies is most likely found only in dog 
TK1. These U antibodies does not recognize the human recombinant TK1 at low 
concentration (eg.1 ng).   
In serum samples, there was no clear cut bands observed with the U antibodies and 
some un specific bands found in the membrane  without  the primary antibody due to 
cross reactivity of secondary antibodies with serum proteins. Sometimes these 
antibodies may detect another compound than TK1 or may cross-react with other 
compounds than TK1. Furthermore modifications of serum TK1 will most likely alter 
the reactivity of different antibodies. It is known that TK1 found in a stable 
multimeric form in serum.  
Human recombinant TK1 (28.2 kDa) has almost similar molecular weight as a 
truncated form of dog recombinant TK1 ∆12 (27.9 kDa). The dimeric form of dog 
recombinant TK1 was identified between 52-72 kDa, which was confirmed by peptide 
analysis (see page 32). The suspected band of  serum TK1 sub unit was identified at 
26 kDa  and it  had a molecular weight  lower than recombinant TK1 due to His tag 
protein in recombinant TK1. The suspected TK1 band was found only in serum from 
dogs with tumor disease and not in serum from healthy dogs. Reducing agents like 
DTT and DTE up to 100 mM concentration did not have clear-cut influence on the 
serum TK1 band. However, with 200 mM concentration of DTE and DTT there was 
reduction in the other unspecific bands in the serum. FPLC gel filtration of serum  
samples on western blot analysis  with antibodies from D have identified both dimer 
and monomer forms of TK1 in tumor diseased serum but not in serum samples from 
healthy dogs.  
Some difficulty was found in obtaining dog cell extracts with sufficient TK1 levels to 
evaluate the function of these antibodies. In one experiment a double band of TK1 
was found in extracts from MDCK cells grown to high cell density. However, in 
extracts from exponentially growing MDCK cells only one band with a molecular 
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weight corresponding to the human cellular TK1 was observed. There would be some 
degradation or phosporylation of cellular TK1, which may responsible for double 
band appearance in dog cell extract. Depletion of albumin from the sera reduced some 
unspecific bands and pre-treatment of serum with anti TK1 antibody removed many 
unspecific bands. This may permit the identification of the TK1 polypeptide in serum. 
Here we identified a protein band of molecular weight at 26 kDa in the serum of dogs 
with tumors, which may be TK1 and this is a major finding in this study.  
Immunoprecipation of serum samples and cell extracts with purified anti dog TK1 
antibodies did not give clear-cut result. There were many unspecific bands in both 
normal and sera from dogs with tumors. One general concern about the antibody-
based assays is that they may be less sensitive than assays based on enzyme activity 
because there is considerable amplification of the signal during the enzyme reaction. 
Therefore, immunologic assays may not be able to determine low concentrations of 
TK1 accurately in sera from healthy individuals. An established immunological assay, 
which measures low concentrations of TK1 from healthy serum, would be an 
alternative to activity measurement. In this project,  purification  of  anti serum to 
isolate C-terminal specific anti dog TK1 antibodies and coupling them with Sepharose 
gave some promising results. A specific TK1 protein of molecular weight at 26 kDa 
was found  in sera from dogs with tumors. However, much further work is needed to 
translate these results to clinically useful methods. 
Tumor markers play an important role in diagnosing cancer in early stages. Even 
though we have many tumor markers in veterinary medicine but there are no specific 
markers that gives clear indications of early stage tumors, which is very important in 
veterinary medicine. In order to produce sensitive, robust and a clinically valuable 
diagnostic test we most likely need antibodies with high specificity that are targeted to 
different epitopes. Owners or veterinarians may not recognize dogs in early stages of 
tumor disease. With the availability of a new immunoassay, it may be possible to 
diagnose the tumors earlier and make treatment more effective. An immunoassay for 
dog lymphomas may be used as a comparative model for non-Hodgkin’s lymphomas 
in humans. The results of this study show that it is possible to produce antibodies that 
can detect TK1 in serum samples from dogs with tumors. This together with results 
from previous studies may provide a cheap and efficient ELISA for malignant 
lymphoma in dogs which may become a reality in the future.  
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Future prospects:   
 
 
 
Using the affinity purified antibodies from rabbit D an ELISA could be developed 
which measures the concentration of TK1 in serum of dogs with tumors. It may 
provide a cheap and convenient test for dogs with tumors. Furthermore, it can help 
veterinarians in treatment monitoring and prognosis of tumors in dogs and decide   
which companion animals should be treated.    
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Appendix: 
 
             1) Amino acid composition of: 
                                    a)  Dog cytosolic TK1 
 
               b)   Dog TK1 (wild type) 
 
                              c)  Recombinant TK1 C-12  
 
                                          d)  Cytoslic Human TK1 
 
 e)    Recombinant human TK1 
 
   2) Peptide analysis results. 
   3) Dog and Human TK1 amino acid sequence. 
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a) Predicted amino acid composition of full length cytosolic TK1 from the dog 
gene sequenced: (Wang L et al in preparation) original sequence is from Gene 
bank.   
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b) Predicted amino acid composition of recombinant full length TK1 from the 
dog (Wang L et al in preparation) original sequence is from Gene bank. 
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c) Predicted amino acid composition of recombinant TK1 of dog with His tag 
protein ∆ 12 (lacking the 12 C-terminal amino acids) (Wang L et al in 
preparation). Original sequence is from Gene bank. 
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d) Predicted amino acid composition of full length human recombinant TK1 with 
His tag protein (Wang L et al in preparation) original sequence is from Gene 
bank. 
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e) Predicted amino acid composition of full length cytosolic TK1 from human 
gene sequenced: (Wang L et al in preparation) original sequence is from Gene 
bank. 
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2) Peptide analysis of 60-70 KDa band of∆ 12 Recombinant dog TK1: 
 
 
 
 
(Source: Å. Engstrom et al .., IMBIM, Uppsala University)            
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                   Dog and Human TK1 amino acid sequence 
 
 
 
                10       20        30        40       50       60    
Dog                   MSCINLPTVL  PGSPSKTRGQ  IQVILGPMFS  GKSTELMRRV  RRFQIAQYKC  LVIKYAKDTR                     
 
Human    MSCINLPTVL  PGSPSKTRGQ  IQVILGPMFS  GKSTELMRRV  RRFQIAQYKC  LVIKYAKDTR  
 
                               70        80        90       100      110       120   
Dog               YSNSFSTHDR  VAVIGIDEGQ  NTMEALPACL  LRDVAQEALG  FFPDIVEFSE  TMANAGKTVI 
 
Human    YSSSFCTHDR  NTMEALPACL  LRDVAQEALG  VAVIGIDEGQ  FFPDIVEFCE  AMANAGKTVI  
 
               130       140       150      160       170       180           
Dog      VAALDGTFQR  KAFGTILNLV  PLAESVVKLT  AVCMECFREA  AYTKRLGSEK  EVEVIGGADK  
 
Human    VAALDGTFQR  KPFGAILNLV  PLAESVVKLT  AVCMECFREA  AYTKRLGTEK  EVEVIGGADK  
 
                190         200          210         220        230               
Dog              YHSVCRLCYF   KKASGPPMGL     DSERNKENVL      VLVPGKPGEG   KEATGVRKLF    
 
Human    YHSVCRLCYF   KKASGQPAGP     DNKEN.....     CPVPGKPGE.    ..AVAARKLF  
 
                   240    
 Dog                       APQHVLQCSPAN  
 
Human     APQQILQCSPAN  
 . 
 
 
 Red color indicates the difference in the amino acid sequence. 
